Skip to main content

Table 2 Incidence rates, hazard ratios and competing risk of active TB associated with Fluticasone/salmeterol relative to Budesonide/formoterol in patients with COPD in intent-to-treat and as treated analysis

From: Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids

Fluticasone/salmeterol cohort

Budesonide/formoterol cohort

Crude HR (95%CI)

Adjustedb HR (95%CI)

Competing risk

subHR (95%CI)

event

Person-Year

IRa

event

Person-Year

IRa

ITT analysis

Before propensity score matching

 TB

358

38,123.37

0.94%

175

28,559.41

0.61%

1.50 (1.26–1.80)

1.41 (1.17–1.70)

1.45 (1.21–1.74)

After propensity score matching

 TB

247

27,392.73

0.90%

172

27,689.85

0.62%

1.34 (1.07–1.69)

1.45 (1.14–1.85)

1.44 (1.19–1.75)

As treated analysis

Before propensity score matching

 TB

126

14,256.75

0.88%

66

10,120.93

0.65%

1.32 (0.98–1.78)

1.28 (0.94–1.73)

1.27 (0.94–1.71)

After propensity score matching

 TB

85

9512.25

0.89%

66

9872.11

0.67%

1.23 (0.73–2.07)

1.38 (0.79–2.42)

1.31 (0.95–1.81)

  1. aIR Incidence rate
  2. bAdjusted for age, gender, propensity score